Cipla launches Yurpeak for the treatment of Obesity and Type 2 Diabetes

New Delhi: Cipla Limited has launched Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) — two of the country’s most pressing health challenges.

The company has the rights to distribute andpromote Yurpeak® — the second brand of Lilly’s tirzepatide in India, after Lilly received DCGI approval.

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and

exercise for the treatment of Type 2 diabetes and Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.

Yurpeak® will be available on prescription in the KwikPen® device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing.

Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: “The launch of Yurpeak® marks a transformative moment in the fight againstobesity and type 2 diabetes mellitus, two of India’s chronic conditions with a heavy burden. Cipla is entering this space with the same depth of expertise and scientific commitmentthat define our leadership in chronic diseases and in respiratory care. Our focus remains on accelerating access to globally benchmarked, future-ready therapies through collaborations like ours with Lilly, which bring together innovation, purpose, and scale to ensure advanced care reaches patients wherever they are.”

Launch of Yurpeak® in India will help expand access to tirzepatide so that more patients can benefit from this innovative therapy. Cipla’s strategic priority is to make it availableacross India, including regions beyond metro cities, leveraging its strong distribution network and deep market insights to drive greater nationwide reach and accessibility. Lilly willmanufacture and supply Yurpeak® to Cipla, and the price will be the same as Mounjaro®.

Cipla will complement the launch of Yurpeak® with comprehensive patient education and support programs, including guidance on dosing, self-administration, and safe, informeduse of the therapy. These initiatives are designed to help patients navigate their treatment confidently and responsibly, in consultation with their healthcare professionals. Thisapproach is backed by Cipla’s long-standing commitment to evidence-based communication and responsible care, empowering individuals to make timely health decisions and adopt sustainable wellness practices.